Peer-Reviewed Publication
Blood2021;137(6):751-762.February 11, 2021Clinical Trial, Phase I
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Geoffrey L Uy1, Ibrahim Aldoss2, Matthew C Foster3, Peter H Sayre4, Matthew J Wieduwilt5, Anjali S Advani6, John E Godwin7, Martha L Arellano8, Kendra L Sweet9, Ashkan Emadi10, Farhad Ravandi11, Harry P Erba12, Michael Byrne13, Laura Michaelis14, Max S Topp15, Norbert Vey16, Fabio Ciceri17, Matteo Giovanni Carrabba17, Stefania Paolini18, Gerwin A Huls19, Mojca Jongen-Lavrencic20, Martin Wermke21, Patrice Chevallier22, Emmanuel Gyan23, Christian Récher24, Patrick J Stiff25, Kristen M Pettit26, Bob Löwenberg20, Sarah E Church27, Erica Anderson28, Jayakumar Vadakekolathu29, Marianne Santaguida28, Michael P Rettig1, John Muth30, Teia Curtis30, Erin Fehr30, Kuo Guo30, Jian Zhao30, Ouiam Bakkacha30, Kenneth Jacobs30, Kathy Tran30, Patrick Kaminker30, Maya Kostova30, Ezio Bonvini30, Roland B Walter31, Jan K Davidson-Moncada30, Sergio Rutella29,32, John F DiPersio1
1Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO.
2Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA.
3Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
4Division of Hematology and Blood and Marrow Transplantation, University of California San Francisco, San Francisco, CA.
5Moores Cancer Center, University of California, San Diego, La Jolla, CA.
6Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
7Providence Cancer Institute, Portland, OR.
8Winship Cancer Institute, Emory University, Atlanta, GA.
9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
10Marlene & Stewart Greenebaum Cancer, School of Medicine, University of Maryland, Baltimore, MD.
11Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
12Division of Hematological Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Centre, Durham, NC.
13Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN.
14Division of Hematology/Oncology, Froedtert Hospital, Medical College of Wisconsin, Milwaukee, WI.
15Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
16Hematologie Clinique, Institut Paoli-Calmettes, Marseille, France.
17Hematology and Bone Marrow Transplantation Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Milan, Italy.
18Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L. and A. Seràgnoli, University of Bologna, Bologna, Italy.
19Hematology, University Medical Center Groningen, Groningen, The Netherlands.
20Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
21Universitätsklinikum Carl Gustav Carus an der Technische Universität, Dresden, Germany.
22Institut Universitaire du Cancer Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
23Centre Hospitalier Universitaire de Nantes, Nantes, France.
24Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU) de Tours, Tours, France.
25Loyola University Medical Center, Maywood, IL.
26Michigan Medicine Bone Marrow Transplant and Leukemia, C. S. Mott Children's Hospital, Ann Arbor, MI.
27NanoString Technologies Inc, Seattle, WA.
28Notable Labs, Foster City, CA.
29John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
30MacroGenics Inc, Rockville, MD.
31Fred Hutchinson Cancer Research Center, Seattle, WA; and.
32Centre for Health, Ageing and Understanding Disease (CHAUD), School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Abstract
Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after <6 months (early relapse [ER]). We have recently shown an association between an immune-infiltrated tumor microenvironment (TME) and resistance to cytarabine-based chemotherapy but responsiveness to flotetuzumab, a bispecific DART antibody-based molecule…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans